Lipidor AB (publ) updates timetable for results from ongoing phase III study – marginal shift in results reporting
“As a result of a minor delay at the CRO (clinical research organization) that conducted the study, we can now conclude that delivery of data from the study to the Swedish statistics consultant who will analyze data and confirm results will coincide with the Christmas and New Year holidays. This means that Lipidor will first receive the results to be presented in January. This marginal delay has no commercial significance for Lipidor,” says Ola Holmlund, CEO, Lipidor AB.
"We have previously communicated that we expected to be able to present the results of the study in December, and since there are many of us who are looking forward to the report of the study results, we would like to announce this change to the timetable.”